Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study

Table 4

Baseline and follow-up data of parameters of echocardiography, hematology, and 6MWD.

	Baseline		1 year		2 year		Difference 1		Difference 2
	Bosentan	Ambrisentan	Bosentan	Ambrisentan	Bosentan	Ambrisentan	Bosentan	Ambrisentan	Bosentan	Ambrisentan
6MWD (m)	432.5 ± 79.1	511.7 ± 41.4	422.3 ± 81.1	517.3 ± 60.8	409.0 ± 92.0	520.0 ± 72.4	10.3 ± 14.5	−5.6 ± 38.9	13.3 ± 29.6	−2.8 ± 21.2
NT-proBNP (pg/ml)	805.1 ± 440.4	516.6 ± 556.3	960.8 ± 673.8	604.7 ± 1247.6	1113.8 ± 902.3	334.3 ± 535.7	−155.4 ± 700.7	−104.8 ± 1375.0	−153.0 ± 376.9	270.3 ± 770.2
SPAP (mmHg)	76.0 ± 43.3	95.3 ± 31.8	71.5 ± 44.9	89.2 ± 38.7	87.8 ± 42.2	83.4 ± 33.9	4.5 ± 20.0	6.2 ± 26.5	−16.4 ± 18.1	5.8 ± 20.9
TAPSE (cm)	1.7 ± 0.4	1.8 ± 0.3	1.8 ± 0.4	1.8 ± 0.3	1.8 ± 0.4	1.8 ± 0.3	−0.14 ± 0.38	−0.01 ± 0.30	0.05 ± 0.21	0.06 ± 0.28
LV EI	1.33 ± 0.32	1.42 ± 0.33	1.28 ± 0.29	1.44 ± 0.36	1.34 ± 0.26	1.28 ± 0.25	0.05 ± 0.16	−0.02 ± 0.49	−0.06 ± 0.23	0.17 ± 0.20
D-dimer (ng/ml)	332.9 ± 204.7	275.4 ± 240.2	218.5 ± 96.0	255.8 ± 153.8	205.6 ± 108.0	301.8 ± 349.7	114.4 ± 135.3	19.7 ± 174.7	12.9 ± 110.9	−46 ± 324.4
PaCO2 (mmHg)	91.7 ± 3.6	94.0 ± 4.5	91.2 ± 3.3	94.6 ± 2.9	92.6 ± 3.1	92.5 ± 5.0	−0.43 ± 1.26	0.61 ± 5.58	1.33 ± 3.04	−2.14 ± 5.65
Uric acid (umol/l)	415.1 ± 93.3	427.9 ± 176.6	368.8 ± 67.6	387.2 ± 92.3	398.9 ± 86.4	415.9 ± 129.8	46.4 ± 54.3	40.8 ± 109.7	−30.1 ± 41.3	−28.8 ± 90.4

Difference 1, deviation of 1 year and baseline; difference 2, deviation of 1 year and 2 year; 6MWD, 6-minute walk distance. .